Table 1. Clinical and Biological... | American Society of Hematology

Table 1.

Clinical and Biological Parameters at Presentation in 42 Patients With MCL and BCL1 Involvement

	Median (Range)
Age yr	68 (40-88)
Hb g/dL	12.5 (7.8-15.0)
WBC × 10⁹/L	8.5 (1.8-840)
Platelet × 10⁹/L	184 (10-677)
LDH U/L	440 (250-1200)
Albumin g/dL	3.8 (3.1-4.9)
	No. of cases/total
Splenomegaly	19/42 (45.2%)
Male/female	29/13
LDH abnormal	18/41 (43.9%)
Advanced stage^*	31/42 (73.8%)
B-symptoms	14/42 (33.3%)
BM involvement^†	27/42 (64.3%)
Leukemic expression^‡	31/42 (73.8%)
Performance status (ECOG)
0-1	36/42 (85.7%)
2-4	6/42 (14.3%)
HISTOLOGY
Diffuse/nodular^1-153	26/2
Classical/blastoid	39/3

	Median (Range)
Age yr	68 (40-88)
Hb g/dL	12.5 (7.8-15.0)
WBC × 10⁹/L	8.5 (1.8-840)
Platelet × 10⁹/L	184 (10-677)
LDH U/L	440 (250-1200)
Albumin g/dL	3.8 (3.1-4.9)
	No. of cases/total
Splenomegaly	19/42 (45.2%)
Male/female	29/13
LDH abnormal	18/41 (43.9%)
Advanced stage^*	31/42 (73.8%)
B-symptoms	14/42 (33.3%)
BM involvement^†	27/42 (64.3%)
Leukemic expression^‡	31/42 (73.8%)
Performance status (ECOG)
0-1	36/42 (85.7%)
2-4	6/42 (14.3%)
HISTOLOGY
Diffuse/nodular^1-153	26/2
Classical/blastoid	39/3

Stage III or IV.

Assessed by bone biopsy in 34 cases and by BM aspirate in 8 cases.

Positive cases defined by >10% CD5/CD19-positive cells in the lymphocyte gate.

The histologic architecture of lymphoma growth was assessed on lymph node specimens and not on bone biopsy sections.